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PCRP and CAD
Prevalence of Low Low-Density
Lipoprotein Cholesterol With Elevated
High Sensitivity C-Reactive Protein in the U.S.
Implications of the JUPITER (Justification for the Use of Statins in
Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) Study
Erin D. Michos, MD, MHS, Roger S. Blumenthal, MD
Baltimore, Maryland
Objectives We assessed the prevalence of low-density lipoprotein-cholesterol (LDL-C) 130 mg/dl with elevated high-
sensitivity C-reactive protein (hsCRP) in the National Health And Nutrition Examination Survey (NHANES),
weighted to be representative of the general U.S. population.
Background Rosuvastatin therapy in the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention
Trial Evaluating Rosuvastatin) study reduced cardiovascular events among older adults with LDL-C 130 mg/dl
and hsCRP 2 mg/l.
Methods Using 1999 to 2004 NHANES data, we categorized men age 50 years and women age 60 years by fasting
LDL-C and hsCRP levels, excluding individuals with prevalent coronary heart disease, coronary heart disease
equivalent (including diabetes), and other JUPITER exclusions.
Results A total of 3.9 million men age 50 years and 2.6 million women age 60 years meeting JUPITER eligibility cri-
teria had fasting LDL-C 130 mg/dl and hsCRP 2 mg/l. In addition, 6.7 million older adults with elevated
hsCRP 2 mg/l have LDL-C levels that exceed their National Cholesterol Education Program goals.
Conclusions Extrapolating JUPITER eligibility to NHANES, an estimated 6.5 million additional adults could be potential candidates
to initiate statin therapy. (J Am Coll Cardiol 2009;53:931–5) © 2009 by the American College of Cardiology
Foundation
















tlasma lipoprotein levels can identify individuals at risk for
ardiovascular disease (CVD) events; however, lipid screen-
ng incompletely identifies individuals likely to benefit from
tatin therapy (1). The National Cholesterol Education
rogram (NCEP) Adult Treatment Panel (ATP)-III uses
ramingham Risk Scores (FRS) to establish treatment
uidelines based on 10-year global risk (2). However, the
ffectiveness of these guidelines to identify asymptomatic
ndividuals at presumptively low-risk for CVD events is
nclear. Limitations of NCEP/ATP-III thresholds for
rom the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease,
ivision of Cardiology, Johns Hopkins University School of Medicine, Baltimore,
aryland. The statistical analysis was funded by AstraZeneca. The National Center
or Health Statistics is the source of data analyzed. Dr. Michos is supported by a Johns
opkins Clinician Scientist Award and American College of Cardiology/Pfizer
areer Development Award. Dr. Michos had full access to the study data and takes
esponsibility for data integrity and accuracy. All analyses, interpretations, and
onclusions are made by the authors and do not represent the views of the National
enter for Health Statistics or funding organizations.t
Manuscript received October 8, 2008; revised manuscript received December 3,
008, accepted December 8, 2008.nstituting lipid-lowering therapy have been highlighted in
revious reports (3,4), underscoring potential missed oppor-
unities for implementing preventive therapies.
The JUPITER (Justification for the Use of Statins in
rimary Prevention: An Intervention Trial Evaluating Ro-
uvastatin) study enrolled adults without known coronary
eart disease (CHD) or CHD equivalent with low-density
ipoprotein cholesterol (LDL-C) 130 mg/dl but high-
ensitivity C-reactive protein (hsCRP) 2 mg/l (5). In this
opulation, which did not qualify for statin therapy based
n NCEP/ATP-III, rosuvastatin reduced major CVD
vents by 44% (5). Using National Health And Nutrition
xamination Survey (NHANES) data, we estimated the
dditional number of U.S. adults who might now be
onsidered for statin therapy.
ethods
HANES is a nationwide probability sample of noninsti-
utionalized U.S. civilians conducted by the National Cen-
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Applying JUPITER Eligibility Criteria to NHANES March 17, 2009:931–5Statistics Institutional Review
Board approved the overall de-
sign; participants provided writ-
ten informed consent. We re-
stricted our analyses to adults age
20 years who had a physical
examination and fasting blood
samples collected from 1999 to
2004 (6). hsCRP was measured
by nephelometry (Dade Behring
Diagnostics Inc., Somerville, New
Jersey) (6).
Population estimates of adults
meeting the JUPITER study eli-
gibility criteria (Table 1) were de-
termined by hsCRP and LDL-C
levels. Those with prior myocar-
dial infarction, stroke, or diabetes
mellitus (fasting glucose 126
mg/dl or use of hypoglyce-
mic agents); those using lipid-
owering medications, estrogen, or immunosuppressants;
r those with serum creatinine 2 mg/dl, triglycerides
500 mg/dl, elevated liver enzymes (alanine aminotrans-
erase 2 upper limit of normal), uncontrolled hyperten-
ion (systolic blood pressure 190 or diastolic 100 mm
g), or cancer diagnosis within 5 years (except nonmela-
oma skin cancer) were excluded from analysis.
The 10-year risk of developing myocardial infarction or
HD death was predicted by FRS (2). Participants were
lassified as low risk (10% 10-year risk and 0 to 1 risk
actors), moderate risk (10% 10-year risk but 2 risk
actors), moderately-high risk (10% to 20% 10-year risk),
nd high risk (20% 10-year risk). The number of partic-
pants with elevated hsCRP who were either below or
t/above their LDL-C goal based on their NCEP/ATP-III
isk level (2) was determined.
Abbreviations
and Acronyms
ATP  Adult Treatment
Panel













NHANES  National Health
And Nutrition Examination
Survey
he JUPITER Study Eligibility Criteria
Table 1 The JUPITER Study Eligibility Criteria
Inclusion Men age 50 yrs, women age 60 yrs
Fasting LDL-C 130 mg/dl
hsCRP 2 mg/l
Exclusion Lipid-lowering, oral hormone, or immunosuppressant therapy
Prior cardiovascular or cerebrovascular event or CHD risk
equivalent including diabetes
Alanine transaminase 2, creatinine kinase 3, or thyroid-
stimulating hormone 1.5 upper limit of normal, creatinine
2 mg/dl, triglycerides500 mg/dl
Systolic blood pressure 190 or diastolic 100 mm Hg
Malignancy within past 5 years except nonmelanoma skin cancer
Chronic inflammatory condition such as severe arthritis, lupus, or
inflammatory bowel disease
ata from Ridker et al. (5).
CHD  coronary heart disease; hsCRP  high-sensitivity C-reactive protein; JUPITER  Justifica-w
ion for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin;
DL-C  low-density lipoprotein cholesterol.Population estimates were determined both for older
dults (men age50 years, women age60 years as per the
UPITER trial) and for all adults age 20 years. Analyses
ere performed using SAS version 9.1 (SAS Institute, Cary,
orth Carolina), and estimates were weighted to the
ivilian noninstitutionalized U.S. population and to account
or the unequal probabilities of selection, oversampling, and
onresponse.
esults
opulation estimates of men age 50 years and women age
60 years with no JUPITER trial exclusion criteria are
ummarized by LDL-C and hsCRP levels (Table 2). An
stimated 3.9 million men and 2.6 million women have
DL-C 130 mg/dl and hsCRP 2 mg/l, including 57%
hites, 15% blacks, 26% Hispanics, and 2% other race/
thnicities. Among adults age 20 years, an estimated 14.5
illion men and 22.2 million women have LDL-C 130
g/dl and hsCRP 2 mg/l (Table 3).
To assess the potential population affected if hypercho-
esterolemic patients initiated statin therapy due to identi-
cation of elevated hsCRP, we estimated the number of
dults with LDL-C levels exceeding NCEP/ATP-III goals
y risk category and hsCRP level (Table 4 for older adults,
able 5 for all adults). Across risk categories, 6.7 million
lder adults and 17.4 million adults age 20 years have
DL-C above goal and also have hsCRP 2 mg/l.
We further assessed how many “normolipidemic” indi-
iduals (those below their recommended NCEP/ATP-III
ipid goals) would be newly eligible to start statin therapy
ecause of an elevated hsCRP 2 mg/l. Approximately 10
illion older adults not eligible for statins per NCEP/ATP-
II (because they were below the LDL-C cutpoint to
onsider pharmacotherapy) might now be considered for
tatins because of elevated hsCRP (Table 4). While not all
opulation Estimates of Men Age >50 and Womenge >60 Years in Millions (95% CI) Meeting theUPITER Study Eligib ity by hsCRP and LDL-C L vels
Table 2
Population Estimates of Men Age >50 and Women
Age >60 Years in Millions (95% CI) Meeting the
JUPITER Study Eligibility by hsCRP and LDL-C Levels
hsCRP, mg/l Sample
Number
of Cases<2 2 to 3 >3
All
LDL 130 mg/dl 6.2 (4.9–7.5) 2.4 (1.8–3.1) 4.1 (3.4–4.8) 531
LDL 130 mg/dl 6.6 (5.2–7.9) 2.6 (1.9–3.3) 5.6 (4.7–6.6) 579
Women
LDL 130 mg/dl 1.6 (1.1–2.1) 1.0 (0.6–1.4) 1.6 (1.3–1.9) 196
LDL 130 mg/dl 2.1 (1.5–2.6) 1.1 (0.8–1.5) 2.5 (1.9–3.1) 240
Men
LDL 130 mg/dl 4.6 (3.6–5.6) 1.4 (0.9–1.9) 2.5 (1.9–3.1) 335
LDL 130 mg/dl 4.5 (3.5–5.4) 1.5 (0.9–2.0) 3.2 (2.5–3.8) 339
I  confidence interval; JUPITER  Justification for the Use of Statins in Primary Prevention: An
ntervention Trial Evaluating Rosuvastatin; LDL low-density lipoprotein; other abbreviations as in
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March 17, 2009:931–5 Applying JUPITER Eligibility Criteria to NHANES20 years below their treatment threshold have hsCRP 2
g/l (Table 5).
iscussion
he JUPITER study showed the benefit of statin therapy in
ndividuals with normal-to-low LDL-C but with an ele-
ated marker of inflammation (5). From NHANES, we
stimate 37 million adults age 20 years without known
HD or equivalent have low-to-normal LDL-C and ele-
ated hsCRP, individuals who may benefit at least from
ore aggressive lifestyle changes. This is higher than 1999
o 2000 estimates, which showed that approximately 12
illion U.S. adults considered “normolipidemic” have ele-
ated hsCRP (7); however, that analysis used a CRP cutoff
f 3 mg/l and considered individuals “normolipidemic”
ased on risk-factor determined LDL-C thresholds, which
ay be higher than the 130 mg/dl threshold used in the
UPITER study. We determined that 6.5 million adults
ith LDL-C130 mg/dl and hsCRP 2 mg/l not currently
n therapy met the “older” age requirement for the JUPITER
tudy and, thus, might now be considered statin candidates.
We also estimated that 17.4 million adults age 20 years
ave LDL-C above the NCEP/ATP-III goal and elevated
sCRP, confirming the need for improved adherence to
uidelines. The JUPITER study might serve as an incentive
o patients and providers to achieve their recommended
DL-C goals.
opulation Estimates of Men Age >50 Years and Women Age >60ears in Millions (95% CI) at NCEP/ATP-III Goals With hsCRP >2 mg
Table 4 Population Estimates of Men Age >50 Years and WomenYears in Millions (95% CI) at NCEP/ATP-III Goals With hs
ATP-III Risk Category Low
Below LDL-C goal* 4.1 (3.4–4.7)
At or above LDL-C goal* 1.2 (0.7–1.7)
Below NCEP cutpoint to consider drug therapy* 5.0 (4.2–5.8)
At or above NCEP cutpoint to consider drug therapy* 0.3 (0.02–0.5)
Below NCEP optional cutpoint for drug therapy* 4.1 (3.4–4.7)
At or above NCEP optional cutpoint for drug therapy* 1.2 (0.8–1.7)
LDL-C goals (mg/dl) and cutpoints to consider drug therapy by risk category: low-risk: goal160, c
Population Estimates of Adults Age >20 Years(95% CI) Mee ng JUPITER S udy Eligibility by h




LDL 130 mg/dl 47.6 (43.1–52.1) 11.
LDL 130 mg/dl 23.9 (20.8–27.0) 8.
Women
LDL 130 mg/dl 21.9 (19.1–24.6) 6.
LDL 130 mg/dl 8.3 (6.6–10.0) 4.
Men
LDL 130 mg/dl 25.8 (23.2–28.4) 5.
LDL 130 mg/dl 15.6 (13.5–17.7) 4.
Abbreviations as in Tables 1 and 2.130, cutpoint 130, optional cutpoint 130; high: goal 100 (optional goal 70), cutpoint 100, op
ATP  Adult Treatment Panel; CI  confidence interval; NCEP  National Cholesterol Education ProgrBecause the NCEP/ATP-III criteria for LDL-C treat-
ent thresholds are based on the FRS, many other risk
actors such as obesity, sedentary lifestyles, inflammation,
amily history of premature CHD, subclinical atherosclero-
is, and chronic renal insufficiency are not taken into
ccount (4,5). The Cardiovascular Prevention Guidelines
or Women (8) have moved away from FRS categories,
ocusing on “at-risk” women because the presence of even 1
ajor risk factor before the age of 50 years confers a higher
ifetime risk for CVD and shorter median survival. Women,
n average, have higher hsCRP levels than men, and
erhaps there should be sex-specific hsCRP cutoffs (9).
hsCRP is strongly associated with the metabolic syn-
rome and obesity (10). With the current epidemic of
besity (11), the prevalence of elevated hsCRP will likely
ncrease as well. Elevated hsCRP has consistently provided
ncremental prognostic value for cardiovascular risk predic-
ion beyond traditional risk factor assessment (1,12).
eight loss (13) and physical activity (14) can lower hsCRP
evels, and lifestyle changes are first-line therapy to lower
VD risk. Statins lower hsCRP levels (15). When lifestyle
hanges alone are not effective in reducing hsCRP, statins
ay be considered in those with elevated risk.
Among those without clinical CVD, 1.5 million
intermediate-risk” adults with elevated hsCRP (75th age/
ex percentile) would now move into the “high-risk” cate-
ory if elevated hsCRP directed treatment strategies (16).
>60
>2 mg/l
Moderate Moderately High High
1.5 (1.0–1.9) 2.2 (1.6–2.9) 0.3 (0.09–0.5)
1.8 (1.2–2.3) 2.9 (2.2–3.7) 0.8 (0.4–1.2)
2.5 (1.9–3.2) 2.2 (1.6–2.9) 0.3 (0.09–0.5)
0.7 (0.4–1.0) 2.9 (2.2–3.7) 0.8 (0.4–1.2)
2.5 (1.9–3.2) 0.8 (0.5–1.1) 0.01 (0.0–0.03)
0.7 (0.4–1.0) 4.4 (3.4–5.3) 1.1 (0.6–1.5)
t190, optional cutpoint160; moderate-risk: goal130, cutpoint160; moderately high: goal
llionsand LDL-C Levels
Years in Millions




14.0) 24.9 (22.3–27.5) 2,379
9.7) 19.1 (16.9–21.2) 1,549
7.6) 16.0 (14.1–18.0) 1,277
5.3) 10.0 (8.7–11.4) 738
6.8) 8.9 (7.6–10.2) 1,102













1 (3.2–tional cutpoint 70.
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Applying JUPITER Eligibility Criteria to NHANES March 17, 2009:931–5The JUPITER study evaluated the benefits of rosuvasta-
in in older individuals (men age 50 and women 60
ears) considered at “lower risk” on the basis of having
ow-to-normal LDL-C. Our study showed that, of older
dults considered “low risk” by NCEP/ATP-III but with
levated hsCRP, 1.2 million have an LDL-C at/exceeding
oal and 4.1 million have LDL-C below goal. Whether this
ame benefit of statin therapy seen in the JUPITER trial of
lder adults would translate to younger individuals is still
nknown. The JUPITER study determined that the num-
er needed to treat at 5 years is 25 (5); with 6.5 million U.S.
dults eligible, this strategy could potentially prevent
60,000 events at 5 years.
tudy limitations. Data for all of the JUPITER study
nclusion/exclusion criteria were not available in NHANES
ncluding thyroid stimulating hormone levels, prior coro-
ary revascularization, and chronic inflammatory condi-
ions. Elevated hsCRP, even in the setting of chronic
nflammatory conditions, confers cardiovascular risk (17).
omen taking estrogen were excluded from our population
stimates. Estrogen use has fallen 66% since 2002 (18), and,
onsequently, these estimates may be lower than seen in
ore contemporary patterns of estrogen use.
onclusions
he JUPITER trial results increase the range of individ-
als potentially benefiting from statin therapy to include
hose at risk for CVD as identified by hsCRP 2 mg/l.
xtrapolating the JUPITER study eligibility to NHANES
weighted to be representative of the general U.S. popula-
ion), we estimate that an additional 3.9 million men age
50 years and 2.6 million women age 60 years could now
e potential candidates for statin therapy. Another potential
ublic health effect would be to encourage untreated or
ndertreated hypercholesterolemic adults who are still above
heir NCEP/ATP-III lipid thresholds and with inflamma-
ion to initiate statin therapy.
cknowledgments
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opulation Estimates of Adults Age >20 Years in Millions (95% CI
Table 5 Population Estimates of Adults Age >20 Years in Milli
ATP-III Risk Category Low
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See Table 4 for LDL-C goals (mg/dl) and cut points to consider drug therapy by risk category.
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